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Background: To describe the neurologic profiles of Rhizomelic chondrodysplasia punctata (RCDP); a peroxisomal
disorder clinically characterized by skeletal abnormalities, congenital cataracts, severe growth and developmental
impairments and immobility of joints. Defective plasmalogen biosynthesis is the main biochemical feature.
Methods: Observational study including review of clinical and biochemical abnormalities, genotype, presence of
seizures and neurophysiological studies of a cohort of 16 patients with RCDP.
Results: Patients with the severe phenotype nearly failed to achieve any motor or cognitive skills, whereas patients
with the milder phenotype had profound intellectual disability but were able to walk and had verbal
communication skills. Eighty-eight percent of patients developed epileptic seizures. The age of onset paralleled the
severity of the clinical and biochemical phenotype. Myoclonic jerks, followed by atypical absences were most
frequently observed. All patients with clinical seizures had interictal encephalographic evidence of epilepsy. Visual
evoked (VEP) and brain auditory potential (BAEP) studies showed initial normal latency times in 93% of patients.
Deterioration of VEP occurred in a minority in both the severe and the milder phenotype. BAEP and somatosensory
evoked potentials (SSEP) were more likely to become abnormal in the severe phenotype. Plasmalogens were
deficient in all patients. In the milder phenotype levels of plasmalogens were significantly higher in erythrocytes
than in the severe phenotype. Phytanic acid levels ranged from normal to severely increased, but had no relation
with the neurological phenotype.
Conclusion: Neurodevelopmental deficits and age-related occurrence of seizures are characteristic of RCDP and are
related to the rest-activity in plasmalogen biosynthesis. Evoked potential studies are more likely to become
abnormal in the severe phenotype, but are of no predictive value in single cases of RCDP.
Keywords: Rhizomelic chondrodysplasia punctata, Skeletal dysplasia, Peroxisome, Plasmalogen, Intellectual disability,
Epilepsy, Evoked potentialsBackground
Rhizomelic chondrodysplasia punctata (RCDP) is a rare
disorder of peroxisomal metabolism, with an estimated in-
cidence of 1:100.000. There are 3 genetic subtypes [1].
RCDP type 1 (OMIM 215100), caused by mutations in the
PEX7 gene, is the most common type [2]. RCDP type 2
(OMIM 222765) and 3 (OMIM 600121) are single enzyme
deficiencies in the plasmalogen biosynthesis pathway [3].
Clinically the 3 genetic subtypes are indistinguishable;* Correspondence: b.t.pollthe@amc.uva.nl
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distribution, and reproduction in any mediumwithin each subtype there is a wide variety in severity of
the disease [4]. At the severe end of the spectrum, the dis-
ease is characterized by a typical facial appearance, con-
genital cataracts, rhizomelia, transient periarticular
calcifications, arthrogenic contractures, somatic growth
impairment and near absence of developmental mile-
stones (Figure 1) [5]. Magnetic Resonance Imaging (MRI)
of the brain shows both developmental and regressive ab-
normalities, including delayed meylination, increased ven-
tricular size and subarachnoidal spaces, supratentorial
myelin abnormalities, progressive cerebellar atrophy and
cervical stenosis [6]. Life expectancy is dramatically short-
ened. In patients with the milder variant, skeletald Central Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 1 A patient with RCDP type 1. Anterior aspect of a patient with the severe phenotype at age 4 years. The clinical phenotype of RCDP is
characterized by facial dysmorphic features, bilateral rhizomelia and arthrogenic contractures. Growth is severely impaired. Patients achieve hardly
any developmental milestones.
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combination of congenital cataracts and developmental
delay is found [7]. The biochemical hallmarks of RCDP
are: 1) decreased concentration of plasmalogens in eryth-
rocytes in all three subtypes [8] and 2) high levels of phy-
tanic acid, which accumulates in an age and diet
dependent way in RCDP type 1. The severity of decreased
erythrocyte plasmalogens corresponds with the severity of
the disease and abnormalities seen on MRI of the brain
[6].
Since plasmalogens are important constituents of neur-
onal membranes, it is assumed that the lack of plasmalo-
gens results in abnormal excitatory activity of neurons in
the central nervous system (CNS) and in abnormal nerve
conduction in both the central and peripheral nervous tis-
sue [9]. We therefore reviewed the medical records of 16
patients with RCDP, with emphasis on the occurrence of
seizures, and related electrophysiological data to clinical
and biochemical parameters within the clinical spectrum
and natural history of RCDP.
Methods
We retrospectively reviewed the medical records and
clinical neurophysiological assessments of 16 patients
with RCDP known to the reference centre for peroxi-
somal disorders in the Netherlands. The diagnosis was
confirmed by biochemical analysis, e.g. RBC plasmalo-
gen levels and plasma phytanic acid levels, and genetic
testing, as previously described [10-13]. Clinical data
were obtained by review of clinical histories and own
observations. We rated patients as either having the severe
or the milder form of RCDP, based on their ability to walk
independently and verbal communication skills. Neurora-
diological features of ten of the patients reported here have
been reported previously [6]. The diagnosis of epilepsy was
based on the physicians’ assessment of a clinical history ofseizures. Semiology, age at onset, frequency of occurrence
and treatment of seizures were recorded. Neurophysio-
logic investigations were conducted by a certified techni-
cian at the AMC. Data interpretation was performed by
one clinical neurophysiologist (JHTMK). All records were
assessed for quality with respect to configuration and
reproducibility.
Ethics approval: Medical- and neurophysiological re-
cords were obtained retrospectively (using patient files)
or to ensure full patient care (considering we noticed
that several of our patients had epilepsy).
Electro encephalography (EEG)
EEGs were recorded with video-monitoring and accord-
ing to the 10–20 system for at least 30 minutes. All
EEG’s were rated on three features: background pattern,
epileptic discharges, and focal abnormalities.
Visual-evoked potentials (VEP)
Stroboscopic flash stimuli were presented, while awake,
monocularly at a distance of 1.45 m with a stimulation
rate of 1.3 Hz. Two series of 100 stimuli presented
to each eye were recorded, superimposed with a Nicolet
Viking IV unit and checked for reproducibility. Record-
ing electrodes were placed over the midocciput and
5 cm laterally on O1 and O2, and referenced to Cz. Elec-
trode impedances were less than 5 kΩ. The bandpass
was 0.16–80 Hz, and the time of analysis was 250 ms.
The P100 latencies were determined.
Somatosensory-evoked potentials (SSEP)
Median nerve SSEPs were recorded with standard proce-
dures [14]. The left or right median nerve was stimu-
lated electrically at the wrist with surface electrodes at a
frequency of 3.1 Hz and stimulus duration of 0.2 mec.
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tracting the latency of N13 to N20.
Brainstem auditory-evoked potentials (BAEP)
Rarefaction clicks with an intensity of 75 dB above the
hearing threshold with a maximum of 95 dB were deliv-
ered. The frequency of stimulation was 11 Hz. Stimuli
were presented monaurally with contra lateral masking
using a noise 40 dB above threshold. Two series of 2000
potentials were recorded, averaged, and superimposed
with a Nicolet Viking IV (Nicolet Instruments Corpor-
ation, Madison, WI, USA). BAEPs were recorded with
surface electrodes over the mastoids and referenced to
C2. Electrode impedances were less than 5 kΩ, the band-
pass was 0.16–3.2 kHz, and the time of analysis was
10 ms. Latencies of wave I to V and I-III and I-V inter-
vals were measured.
The BAEP, VEP, and SSEP studies were all reviewed by
an independent observer (JHTMK) and scored as: (1)
normal; (2) mildly abnormal (+ 2–4 SD); and (3) mark-
edly abnormal (>4 SD), based on our references.
Results
In this cohort 15 patients had RCDP type 1 (PEX7) and
one patient had RCDP type 2 (GNPAT, glyceronepho-
sphate O-acyltransferase). Nine patients with the severe
phenotype were homozygous for the most common mu-
tation (L292X) in PEX7. The missense mutation H285R
was seen in the patients with the milder phenotype. In 2
only one mutation in PEX7 was found. In patient 5 gene
expression studies revealed a homozygous expression of
the heterozygous mutation at L292X. The patient with
RCDP type 2 had a severe phenotype similar to the pa-
tients with RCDP type 1.
Duration of follow up ranged from 7 months to 30 years
(median 8.3 years, mean 10.8 years). Twelve patients were
severely affected, whereas 4 had a milder phenotype. Pa-
tients with the severe phenotype only reached the earliest
developmental milestones. Minor improvements in social
interaction, awareness of their surroundings and grabbing
with their fingers were present. The majority of patients
required tube-feeding, because of impaired sucking and
swallowing. At neurological examination visual responses
were brief despite of cataract extraction and aphakia cor-
rection. There was axial hypotonia and spastic tetrapar-
esis, with increased tendon reflexes and positive Babinski
signs.
In patients with the milder phenotype delayed motor
development was noticed in the second half of the first
year. Patient 14 attained the ability to walk independ-
ently at age 1.5 year; the other 3 patients (patients 13,
15, 16) were over 2 years (range 2–8 yrs). Speech and
language development was also delayed. Patients were
able to feed themselves. All 4 patients attended schoolsfor children with special needs. Patients who reached
adulthood (patient 15, 16) needed round-the-clock care
facility. With increasing age they lost ambulation ability,
mostly due to arthrogenic contractures. The neurological
examination was characterized by intellectual disability,
contractures of the large joints and scoliosis. Pyramidal
tract signs were present in patient 16. Table 1 depicts
clinical (including MRI findings [6]) and biochemical
characteristics of this cohort. Patients with the milder
phenotype had significantly higher levels of plasmalo-
gens in erythrocytes. Phytanic acid levels in plasma
varied.
Epilepsy occurred in the severe (11/12) and the milder
(3/4) phenotype (Table 2). There was a significant differ-
ence in age-related onset of seizures between the severe
and the milder phenotype (Table 3). In the severe pheno-
type, ages at onset of epilepsy varied between 4 months
and 11 years (median 2.5 years, mean 3.8 years). Patients
who survived into school age all developed epilepsy. In the
milder phenotype seizures did not occur before age 7 years.
Seizure frequency and seizure type varied considerably.
Some patients had multiple seizures a day whereas others
only had seizures during febrile episodes. Some patients
suffered from more than one seizure type. Myoclonic jerks
were the most frequent type of seizures reported in pa-
tients with the severe phenotype of RCDP. In patients with
the milder phenotype brief periods of staring and a frozen
facial expression occurred, without the typical 3 Hz spike
and slow wave discharges seen on EEG. All treatment in
RCDP was aimed at achieving a reasonable quality of life.
Since patients experienced discomfort from the frequent
seizures, anti epileptic drugs (AED) were prescribed. So-
dium valproate was the most commonly used AED (75%).
Although generally effective, in patients with the severe
phenotype myoclonic epilepsy seizure control was not
fully achieved. Parents reported that side effects (drowsi-
ness) of medication were more invalidating to the patient
than seizures were on their own. No renal or hepatic side
effects were noticed.
A total of 63 EEGs were conducted. Interictal back-
ground EEG rhythms were initially normal in 10/16.
Non-epileptiform focal or multifocal abnormal activity
occurred in 12/16. Deterioration to slow and less or-
ganized patterns (Figure 2), with diminished (to absent)
reactivity on stimuli occurred in 7 patients with the se-
vere phenotype. Patients with the severe phenotype that
did not show epileptiform discharges on EEG were
under the age of 1 year. During EEG recording, EEG
seizure discharges correlating with clinical seizure activ-
ity was seen in 7/14.
Evoked potential study results are summarized in
Table 2. A total of 39 VEPs were performed in 10 with
the severe and 4 patients with the milder phenotype.
Follow up examinations were performed in 8 with the




















Ages (mo) at MRI
and findings
Remarks
1 Severe PEX 7:c [875 T > A];
[875 T > A]
nd nd 10 7 Smiles responsively, no
intentional movement,
gastrostomy fed
24: Wide extra cerebral liquor
spaces; ventricular enlargement;
cerebellar atrophy; abnormal





2 Severe PEX 7:c [875 T > A];
[875 T > A]
1.2 0.5 6.4 3 Smiles responsively,
spontaneous movement of
fingers, bottle/spoon fed
23 and 48: Delayed myelination,





3 Severe PEX 7:c [875 T > A];
[875 T > A]
0 0 12.4 3 Smiles responsively, turns
from back to belly,
gastrostomy fed
10, 22 and 60: Delayed myelination;
abnormal white matter signal
intensity; progressive cerebellar
atrophy. Narrow cervical canal.
Ref [6]
pt 3.
4 Severe PEX 7:c [875 T > A];
[875 T > A]
0.2 0.2 4.4 3 Smiles responsively, no
intentional movement,
gastrostomy fed
2 and 16: Delayed myelination;
abnormal white signal intensity;
cerebellar atrophy; progressive
ventricular enlargement. Progressive





5 Severe PEX 7:c
[875 T > A];?
1.6 2.9 25.2 5 Smiles responsively, vocalize
spontaneous movement
of fingers, gastrostomy fed
10, 27 and 48: Delayed myelination;






6 Severe PEX 7:c [875 T > A];
[875 T > A]
0.6 0.2 9.1 3 Smiles responsively, vocalize
no intentional movement,
bottle/spoon/gastrostomy fe
3 and 14: Ventricular enlargement;
frontal hygroma; delayed myelination;
abnormal white matter signal






7 Severe PEX 7:c [875 T > A];
[875 T > A]
0.2 0.1 6.2 35 Eye contact, No intentiona
movement, gastrostomy fed
1 week. Wide fissura Silvii, no other
abnormalities.
8 Severe PEX 7:c [875 T > A];
[649G > A]
0.2 0.4 7 5 Smiles responsively, vocalize
scarce spontaneous
movement, gastrostomy fed
Not performed. † 3 yrs
2/12
9 Severe PEX 7:c [875 T > A];
[875 T > A]
1.7 1.4 25.3 11 Smiles responsively, no
intentional movement,
primarily tube fed
9 and 21: Delayed myelination;
abnormal white matter signal
intensity; ventricular enlargement;
progressive cerebellar atrophy.
Relatively narrow cervical canal.
† 2 yrs
7/12
10 Severe PEX 7:c [875 T > A];
[875 T > A]
2.1 1.0 15 6 Responds to sounds, no
intentional movement, prima
fed by gastrostomy



























Table 1 Patient characteristics and peroxisomal test results (Continued)
11 Severe PEX 7:c [875 T > A];
[875 T > A]
0 0 3.4 Not performed Smiles responsively, scarce
spontaneous movement,
primarily tube fed
4: Delayed myelination; wide




12 Severe DHAPAT:c [924 + 5G > C];
[924 + 5G > C]
0.3 1.2 1.0 Infancy No intentional movement,
gastric tube fed
Not performed.
13 Mild PEX 7:c [875 T > A];/
[854A > G]
5.2 12.1 158.7 4 IQ < 50, walks short
distances independently





14* Mild PEX 7:c [854A > G];
[854A > G]
2.4 6.5 154.1 5 IQ < 50, rides a tricycle 90: Normal findings. Diagnosis
at age
6 yrs
15 Mild PEX 7:c [875 T > A];/? 4 8.5 8.9 24 Autistic features, IQ < 50,
walks short distances
independently





16 Mild PEX 7:c [875 T > A];/
[854A > G]













♦ Biochemical analysis at time of diagnosis. *Mildest patient in this cohort. Plasmalogens (C16:0DMA/C16:0 and C18:0DMA/C18:0%) measured in RBCs. Phytanic acid measured in plasma. ?: In two patients only one








































1 2 Myoclonic Daily 2.0-4.2 M ➔ Mo Focal + 3.1 – 4.2 N ➔ N N ➔ N -
2 11 Myoclonic; generalized
tonic-clonic
Weekly 0.8-11.7 N ➔ S Focal + (≥ 3.8 yrs) 0.8 - 9.1 N ➔ S N ➔ S NCR
3 4 1. Fever induced
generalized tonic-clonic;





0.8-8.6 N ➔ S Multifocal + (≥ 2.9 yrs) 0.8 - 6.9 N ➔ S N ➔N N ➔ M
4 0.3 Tonic; smacking Daily 0.0-1.3 N ➔ S Multifocal + (≥ 0.5 yrs 0 - 0.3 N ➔ S N ➔N -
5 3 Myoclonic; gelastic;
atypical absence
Daily 0.9-4.5 M ➔ Mo Focal ➔ multifocal + (≥ 0.9 yrs) 1.3 - 4.5 N ➔ M N ➔ M NCR/S
6 2 Myoclonic; status
epilepticus
Daily (clustered) 0.2-2.4 N ➔ S Focal ➔ multifocal + (≥ 1.1 yrs)
St epilepticus
0.2 - 2.3 N ➔ N N ➔ N NCR
7 2 Myoclonic-tonic; gelastic Daily 0.0-4.0 N ➔ M + (≥ 2.3 yrs) 0 -1.8 N N ➔ N N
8 0.8 Tonic Fever induced 0.0-2.2 N 0 N M -
9 1 Generalized tonic-clonic Single, fever induced 0.7-1.7 N ➔ M Multifocal + (≥1.1 yrs) 0.5 - 1.7 N ➔ N N ➔N -
10 5 1. Facial myoclonic; 2. tonic 1. Daily;
2. Monthly
5.6 N Focal + - - - -
11 0.3 M + 0.3 N N M
12 10 Myoclonic Daily 26.7 M Focal + - - - -
13 5.4-7.3 N ➔ N Focal + (≥ 5.4 yrs) 5.4 - 7.3 N ➔ N N ➔ N N ➔ N
14 7 Atypical absences Weekly 6.5-8.3 M + (≥ 6.5 yrs) 6.5 - 7.5 N ➔ N M ➔ N N ➔ N
15 21 Generalized tonic-clonic Single 9.3-23.1 M Focal➔ multifocal + (21 yrs) 9.3 - 23.1 N ➔ N N ➔ M N
16 20 Atypical absence Monthly 13.3-29.5 Mo ➔ Mo Multifocal + (≥ 13.3 yrs) 10 - 17 N N ➔ N -
N: normal; M: mildly abnormal EEG for age/mildly increased latencies (+2-4 SD), Mo: moderately abnormal EEG background pattern, S: severely abnormal EEG pattern for age/markedly increased latencies (> +4 SD).





















Table 3 Incidence of seizures per age group
Age,
y
RCDP cases in this
cohort1
Number of cases with epilepsy (%)1
Total (Severe/mild) Severe phenotype Mild phenotype3
<1 16 (12/4) 2/12 (17%) 0/4 (0%)
1–4 152 (11/4) 9/11 (82%) 0/4 (0%)
4–12 102 (6/4) 6/6 (100%) 1/4(25%)
>12 52 (2/3) 2/2 (100%) 2/3 (67%)
1Patients younger at time of analysis and patients deceased are excluded.
2One patient died at age <1 yrs; 4 patients died at age 1–4; 2 patients died
at age 4–12 yrs. 3Patients with the milder phenotype were diagnosed after
age 4 years.
y: years.
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12/14 the initial latencies were normal. Deterioration
occurred in 3 (2 patients with the severe phenotype and
1 patient with the milder phenotype). All patients un-
derwent lens extraction because of bilateral congenital
cataracts. There was no relationship between the time of
lens extraction and functional integrity of the visual
system as measured by VEP.
A total of 34 BAEPs are available from 10 with the se-
vere and 3 patients with the milder phenotype, with fol-
low up in 10. Initial BAEPs were all normal. In 4/7
patients with the severe phenotype in whom follow up
was performed, central prolonged conduction times at
BAEP occurred in time. In patients with the milder
phenotype, latencies were normal.
Eighteen SSEPs were recorded in 6 with the severe
and 3 with the milder phenotype. In the patients withFigure 2 Change in EEG pattern in a patient with the severe phenoty
10 months. Development of background pattern at 3 years. Deterioration o
regions at 8 years.the milder phenotype latencies were normal. Two pa-
tients with the severe phenotype had normal conduction
times. In 2 patients latencies were increased and in an-
other 2 no cortical responses could be detected. These
patients also showed stenosis of the cervical spinal canal
on MRI, even though there were no signs of myelum
compression [6].
Discussion
In this report we charted the long term follow-up of a
cohort of 16 patients with RCDP and correlated the out-
come to the severity of the genetic and metabolic defects
(the largest series so far). Patients with both the mild
and the severe phenotype are represented and biochem-
ical and genetical data are available of all patients.
The clinical neurologic presentation of patients at the
severe end of the RCDP spectrum is quite homogenous,
with profound epilepsy, spasticity and near absent de-
velopment. Decay in neurologic skills is not typical,
although interaction with the surrounding is less in pe-
riods of illness and frequent seizures [15]. Less is known
about the disease course of patients with the milder
phenotype of the disorder [4,6,16,17]. In this cohort, 4
patients with the milder clinical and biochemical pheno-
type are represented. They attain more advanced devel-
opmental skills than patients with the severe phenotype.
The 2 eldest patients become less ambulant with time.
Patients with the milder phenotype have significant
higher levels of plasmalogens in red blood cells. The im-
portance of plasmalogens in the neurological profile is
further emphasized by the fact that the patient with ape of RCDP. EEG recordings of patient 3. Normal for age at
f background pattern and runs of spike wave complexes in the frontal
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comparable to the patients with the severe variant of
RCDP type 1.
In order to unravel the effects of plasmalogen defi-
ciency in vivo, several mouse models for both the severe
and milder variant of RCDP type 1, 2 and 3 have been
generated. As in the patients, the severity of the clinical
phenotype in mice is related to the residual capacity in
plasmalogen biosynthesis. Eye, brain and bone abnor-
malities resemble the abnormalities seen in patients with
RCDP. Growth is impaired. Life expectancy appears to be
dependent on the ability to survive a critical period after
birth in Pex7−/−, but is normal in the Pex7neo/neo mice
[18-21]. Epilepsy has not been mentioned in the mice.
Seizures represent a significant clinical problem in
RCDP. Our results on the occurrence of seizures are in
agreement with earlier studies [16]. However, previous
studies have not considered the impact of the severity of
biochemical defects and specific mutations in relation to
epilepsy [22,23]. We found that epilepsy occurs fre-
quently in RCDP patients irrespective of genotype or
phenotype. However, a clear distinction between patients
with the mild and the severe phenotype existed in the
age at onset of epilepsy. This implicates that there is a
relation between the development of seizures and the
amounts of residual plasmalogens. This is in agreement
with the current knowledge about plasmalogen distribu-
tion and function since they are known to be abundant
in gray matter where they play an active metabolic role
[8,24]. We were particularly interested in the latencies of
evoked potentials as a reflection of myelination, since in
humans plasmalogens constitute the majority of total
phospholipids in the white matter and signal abnormal-
ities on MRI are present in patients with the severe, but
not the milder phenotype of RCDP [6,8]. We found that
93% of VEP latencies were initially normal for age and
that deterioration occurred in 31% of patients with both
the severe and mild phenotype. Because both mouse
models for severe RCDP (PEX7−/− and GNPAT−/−) show
hypoplasia of the optic nerves [25], we are quite sur-
prised that VEPs were relatively spared and that there is
no obvious difference between patients with the severe
and mild phenotype. BAEPs and SSEPs are more likely
to be abnormal in the patients with the severe pheno-
type. This indicates a loss of integrity of the brainstem
auditory system and the lemniscal and thalamocortical
pathways in the brain in some of the patients with the
severe phenotype of RCDP. Indeed, both delayed myelin-
ation and dysmyelination are described in RCDP pa-
tients [6,26,27]. Currently we do not have an explanation
why some of our most severely affected individuals have
normal evoked potentials.
In conclusion, the age related occurrence of epilepsy
and the severe, but variable defects in motor andcognitive functioning of patients, illustrates the import-
ance of plasmalogens for normal neurodevelopment.
Evoked potentials are more likely to become abnormal
in patients with low amounts of plasmalogens, but have
no predictive value in single cases.
Consent
Written informed consent for publication of Figure 1
was given by the parents of the patient.
Competing interest
The authors declare that they have no competing interests.
Authors’ contributions
AB: Design of the study, interpretation of data, drafting manuscript. JK:
Interpretation of EEGs and EP studies, revising the manuscript. HW: Providing
biochemical and genetic information, revising the manuscript. PB:
Interpretation of data, revising the manuscript. BP: Guarantor, design of the
study, interpretation of data, revising manuscript. All authors read and
approved the final manuscript.
Acknowledgement
The authors thank Thijs Boeree for preparing Figure 2.
Author details
1Department of Pediatric Neurology/Emma Children’s Hospital, Academic
Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
2Department of Neurology, Academic Medical Center of Amsterdam,
Amsterdam, The Netherlands. 3Laboratory of Genetic Metabolic Diseases,
Academic Medical Center of Amsterdam, Amsterdam, The Netherlands.
4Meibergdreef 9, Amsterdam 1105 AZ, The Netherlands.
Received: 25 June 2013 Accepted: 5 October 2013
Published: 30 October 2013
References
1. Heymans HS, Oorthuys JW, Nelck G, Wanders RJ, Schutgens RB: Rhizomelic
chondrodysplasia punctata: another peroxisomal disorder. N Engl J Med
1985, 313:187–188.
2. Braverman N, Steel G, Obie C, Moser A, Moser H, Gould SJ, Valle D: Human
PEX7 encodes the peroxisomal PTS2 receptor and is responsible for
rhizomelic chondrodysplasia punctata. Nat Genet 1997, 15:369–376.
3. Wanders RJ, Waterham HR: Peroxisomal disorders I: biochemistry and
genetics of peroxisome biogenesis disorders. Clin Genet 2005, 67:107–133.
4. Barth PG, Wanders RJA, Schutgens RBH, Staalman CR: Variant rhizomelic
chondrodysplasia punctata (RCDP) with normal plasma phytanic acid:
clinico-biochemical delineation of a subtype and complementation
studies. Am J Med Genet 1996, 62:164–168.
5. Spranger JW, Opitz JM, Bidder U: Heterogeneity of chondrodysplasia
punctata. Humangenetik 1971, 11:190–212.
6. Bams-Mengerink AM, Majoie CB, Duran M, Wanders RJ, Van Hove J,
Scheurder CD, Barth PG, Poll-The BT: MRI of the brain and cervical spinal
cord in Rhizomelic chondrodysplasia punctata. Neurology 2006,
66:798–803.
7. Wijburg MT, Wenniger-Prick LJ, Bosch AM, Bams-Mengerink AM, Visser G:
Bilateral cataract in childhood years: always an indication for screening
on a metabolic disorder. Ned Tijdschr Geneeskd 2008, 152:632–636.
8. Braverman NE, Moser AB: Functions of plasmalogen lipids in health and
disease. Biochim Biophys Acta 2012, 1822:1442–1452.
9. Brites P, Ferreira AS, da Silva TF, Sousa VF, Malheiro AR, Duran M, Waterham HR,
Baes M, Wanders RJ: Alkyl-glycerol rescues plasmalogen levels and pathology
of ether-phospholipid deficient mice. PLoS One 2011, 6(12):e28539.
10. Dacremont G, Vincent G: Assay of plasmalogens and polyunsaturated
fatty acids (PUFA) in erythrocytes and fibroblasts. J Inherit Metab Dis 1995,
18:84–89.
11. Dacremont G, Cocquyt G, Vincent G: Measurement of very long-chain fatty
acids, phytanic and pristanic acid in plasma and cultured fibroblasts by
gas chromatography. J Inherit Metab Dis 1995, 18:76–83.
Bams-Mengerink et al. Orphanet Journal of Rare Diseases 2013, 8:174 Page 9 of 9
http://www.ojrd.com/content/8/1/17412. Wanders RJ, Ofman R, Romeijn GJ, Schutgens RB, Mooijer PA, Dekker C, van
den Bosch H: Measurement of dihydroxyacetone-phosphate acyltransferase
(DHAPAT) in chorionic villous samples, blood cells and cultured cells.
J Inherit Metab Dis 1995, 18:90–100.
13. Motley AM, Brites P, Gerez L, Hogenhout E, Haasjes J, Benne R, Tabak HF,
Wanders RJA, Waterham HR: Mutational spectrum in the PEX7 gene and
functional analysis of mutant alleles in 78 patients with rhizomelic
chondrodysplasia punctata type 1. Am J Hum Genet 2002, 70:612–624.
14. Zandbergen EG, Hijdra A, de Haan RJ, van Dijk JG, Ongerboer de Visser BW,
Spaans F, Tavy DL, Koelman JH: Interobserver variation in the interpretation
of SSEPs in inanoxic-ischaemic coma. Clin Neurophysiol 2006, 117:1529–1535.
15. White AL, Modaff P, Holland-Morris F, Pauli RM: Natural history of rhizome-
lic chondrodysplasia punctata. Am J Med Genet A 2003, 118A:332–342.
16. Braverman N, Chen L, Lin P, Obie C, Steel G, Douglas P, Chakraborty PK,
Clarke JT, Boneh A, Moser A, Moser H, Valle D: Mutation analysis of PEX7 in
60 probands with Rhizomelic chondrodysplasia punctata and functional
correlations of genotype with phenotype. Hum Mutat 2000, 20:284–297.
17. Smeitink JAM, Beemer FA, Espeel M, Donkerwolcke RAMG, Jacobs C,
Wanders RJA, Schutgens RB, Roels F, Duran M, Dorland L, Berger R,
Poll-The BT: Bone dysplasia associated with phytanic acid accumulation
and deficient plasmalogen synthesis: a peroxisomal entity amenable to
plasmaferesis. J Inherit Metab Dis 1992, 15:377–380.
18. Brites P, Motley AM, Gressens P, Mooyer PA, Ploegaert I, Everts V, Evrard P,
Carmeliet P, Dewerchin M, Schoonjans L, Duran M, Waterham HR, Wanders
RJ, Baes M: Impaired neuronal migration and endochondral ossification
in Pex7 knockout mice: a model for rhizomelic chondrodysplasia
punctata. Hum Mol Genet 2003, 12:2255–2267.
19. Braverman N, Zhang R, Chen L, Nimmoa G, Schepers S, Tran T, Chaudhury
R, Moser A, Steinberg S: A Pex7 hypomorphic mouse model for
plasmalogen deficiency affecting the lens and skeleton. Mol Genet Metab
2010, 99:408–416.
20. Rodemer C, Thai TP, Brugger B, Kaercher T, Werner H, Nave KA, Wieland F,
Gorgas K, Just WW: Inactivation of ether lipid biosynthesis causes maile
infertility, defects in eye development and optic nerve hypoplasia in
mice. Hum Mol Genet 2003, 12:1881–1895.
21. Liegel R, Chang B, Dubielzig R, Sidjanin DJ: Blinkd sterile 2 (bs2), a
hypomorphic mutation in AGPS, results in cataracts and male sterility in
mice. Mol Genet Metab 2011, 103:51–59.
22. Lenti C, Paganoni P, Sangermani R: Rhizomelic chondrodysplasia punctata:
16-year follow up of a child from birth. Ital J Neurol Sci 1991, 12:469–473.
23. Takahashi Y, Suzuki Y, Kumazaki K, Tanabe Y, Akaboshi S, Miura K,
Shimozawa N, Kondo N, Nishiguchi T, Terada K, Orii T: Epilepsy in
peroxisomal diseases. Epilepsia 1997, 38:182–188.
24. Rosenberger TA, Oki J, Purdon AD, Rapoport SI, Murphy EJ: Rapid synthesis
and turnormver of brain microsomal ether phospholipids in the adult
rat. J Lipid Res 2002, 43:59–68.
25. Feirreira da Silva T, Sousa VF, Malheiro AR, Brites P: The importance of
ether-phospholipids: a view from the perspective of mouse models.
Biochem Biophys Acta 2012, 1822:1501–1508.
26. Powers JM, Kenjarski TP, Moser AB, Moser HW: Cerebellar atrophy in
chronic rhizomelic chondrodysplasia punctata: a potential role for
phytanic acid and calcium in the death of its Purkinje cells. Acta
Neuropathol 1999, 98:129–134.
27. Agamanolis DP, Novak RW: Rhizomelic chondrodysplasia punctata: report
of a case with review of the literature and correlation with other
peroxisomal disorders. Pediatr Pathol Lab Med 1995, 15:503–513.
doi:10.1186/1750-1172-8-174
Cite this article as: Bams-Mengerink et al.: The neurology of rhizomelic
chondrodysplasia punctata. Orphanet Journal of Rare Diseases 2013 8:174.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
